Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
Asymmetric synthesis of novel spirocycles via a chiral phosphoric acid catalyzed desymmetrization
作者:Amber M. Kelley、Eni Minerali、Jennifer E. Wilent、Nicholas J. Chambers、Kyla J. Stingley、G. Tyler Wilson、Kimberly S. Petersen
DOI:10.1016/j.tetlet.2019.03.074
日期:2019.5
A straightforward method for the asymmetric preparation of novel lactone and lactam spirocycles is described. An initial desymmetrization via a chiral Brønsted acid yields enantioenriched lactones which readily undergo a second cyclization to give the desired spirocycle.
USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS
申请人:Bayer Aktiengesellschaft
公开号:EP1217994A2
公开(公告)日:2002-07-03
US6900194B1
申请人:——
公开号:US6900194B1
公开(公告)日:2005-05-31
[EN] USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS<br/>[FR] UTILISATION DE DERIVES D'ACIDE 4-BIARYLBUTYRIQUE ET D'ACIDE 5-BIARYLPENTANOIQUE SUBSTITUES POUR LE TRAITEMENT DE LA SCLEROSE EN PLAQUES
申请人:BAYER AG
公开号:WO2001022951A2
公开(公告)日:2001-04-05
Use of substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Prevention and Treatment of Multiple Sclerosis, pharmaceutical compositions containing them, and a process for using them. The compounds of the invention have the generalized formula (T)xA-B-D-E-CO2H wherein A is an aryl or heteroaryl rings; B is an aryl or heteroaryl ring or a bond; each T is a substituent group; x is 0, 1, or 2; the group D represents Formulae (a) or (b), the group E represents a two or three carbon chain bearing one to three substituent groups which are independent or are involved in ring formation, possible structures being shown in the text and claims; and each of the substituents on E is an independent substituent; and include pharmaceutically acceptable salts thereof.